Advertisement: Bridge Fibre mid
Advertisement Cambridge China Centre
Advertisement: Lynch Wood Park
Advertisement: RSM
RealVNC mid banner careers
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: Bradfield Centre mid
Advertisement EY mid banner
Advertisement: CBM
RealVNC mid-banner general
Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
Barr Ellison Solicitors – commercial property
6 August, 2018 - 15:56 By Kate Sweeney

Avacta hits right note for Bach BioSciences

Avacta laboratory

Avacta Group in Cambridge, which develops Affimer® biotherapeutics and reagents, has struck a key deal with a US partner. 

Avacta has agreed a co-development partnership with Bach BioSciences, which is commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston.
The collaboration will develop a new class of Affimer drug conjugate therapies with a novel mode of action that combines Avacta’s Affimer technology with drug conjugates developed at Tufts.

In a ground-breaking co-invention with Tufts, the company has devised a new class of drug conjugate. This selectively releases a potent drug in the tumour microenvironment without requiring cellular internalisation of the conjugate as is otherwise the case with traditional antibody-drug conjugates. Avacta and Tufts have jointly filed for broad patent protection for this inventive concept. 

The patent covers Affimers and a wide range of other binders, against oncology, viral and inflammatory targets that are not internalised rapidly enough to be useful in traditional antibody-drug conjugates. 

Newsletter Subscription

Stay informed of the latest news and features